Actuate Therapeutics, Inc. Common stock (ACTU)
Nasdaq · Healthcare · Biotechnology
$0.8749+6.83%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $21.0M
- 52-week range
- $0.604 – $8.49
- 52-week change
- −88.37%
- EPS (trailing)
- −$0.96
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$22.2M
- Diluted EPS
- −$1.06
From the company’s annual report on SEC EDGAR.
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Headquarters: Fort Worth, United States · 12 employees · actuatetherapeutics.com